NCT06941350

A Trial to Evaluate the Safety and Efficacy of NCR102 in Subjects With aGVHD

A Phase I/II Clinical Study Evaluating the Safety and Efficacy of NCR102 Injection in the Treatment of Acute Graft-versus-Host Disease (aGVHD)

• Status: Not Yet Recruiting
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 24 (estimated)
• Sponsor: Nuwacell Biotechnologies Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Evaluate the safety and efficacy of NCR102 injection in the treatment of SR-aGVHD patients who have failed second-line therapy.

Detailed description

An open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability and preliminary efficacy of NCR102 injection in the treatment of SR-aGVHD patients who have failed second-line therapy.

Conditions

• Acute Graft-versus-Host Disease

Interventions

Type	Name	Description
BIOLOGICAL	NCR102 injection	Twice a week for 4 weeks, and the treatment continues for another 4 weeks in subjects with partial remission by day 28.

Timeline

• Start date: 2025-04-28
• Primary completion: 2026-10-30
• Completion: 2027-05-30
• First posted: 2025-04-23
• Last updated: 2025-04-23